To this end, in the recent past, Iyer et al. [14] demonstrated that more extensive lymph node involvement is correlated with decreased survival, and just this past year, taking advantage of the tumor’s programmed-death-ligand-1 (PD-L1) expression, a report showed a 56% objective response rate when patients with advanced MCC were treated with pembrolizumab [31]. The gene discussed is CD274; the disease is neoplasm.